Association Studies Suggest a Key Role for Endothelin-1 in the Pathogenesis of Preeclampsia and the Accompanying Renin-Angiotensin-Aldosterone System Suppression

Hypertension

Volumn 65, Issue 6, 2015, Pages 1316-1323

  Verdonk, Koen ^a   Saleh, Langeza ^a   Lankhorst, Stephanie ^a   Smilde, J E Ilse ^a   Van Ingen, Manon M ^a   Garrelds, Ingrid M ^a   Friesema, Edith C H ^a   Russcher, Henk ^a   Van Den Meiracker, Anton H ^a   Visser, Willy ^a   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

angiotensin II type 2 receptor; renin

Indexed keywords

ALDOSTERONE; ANGIOTENSINOGEN; CREATININE; ENDOTHELIN 1; PLACENTAL GROWTH FACTOR; RENIN; VASCULOTROPIN RECEPTOR 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CESAREAN SECTION; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION; HUMAN; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINALYSIS; URINE LEVEL; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACENTA CIRCULATION; PREGNANCY; PREGNANCY OUTCOME; REFERENCE VALUE; RISK ASSESSMENT;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CREATININE; ENDOTHELIN-1; FEMALE; HUMANS; PLACENTAL CIRCULATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; REFERENCE VALUES; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT;

EID: 84937545842     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05267     Document Type: Article

References (31)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-644. doi: 10.1016/S0140-6736(10)60279-6.
2. Verdonk K, Visser W, Van Den Meiracker AH, Danser AH. The reninangiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond). 2014;126:537-544. doi: 10.1042/CS20130455.
3. Brown MA, Reiter L, Rodger A, Whitworth JA. Impaired renin stimulation in pre-eclampsia. Clin Sci (Lond). 1994;86:575-581.
4. Brown MA, Wang J, Whitworth JA. The renin-angiotensin-aldosterone system in pre-eclampsia. Clin Exp Hypertens. 1997;19:713-726. doi: 10.3109/10641969709083181.
5. Rana S, Karumanchi SA, Lindheimer MD. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014;63:198-202. doi: 10.1161/HYPERTENSIONAHA.113.02293.
6. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675-681. doi: 10.1161/HYPERTENSIONAHA. 109.149690.
7. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, Wesseling S, Strevens H, Danser AH, van den Meiracker AH. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295-302. doi: 10.1161/HYPERTENSIONAHA.111.173559.
8. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, Baelde HJ, Danser AH, van den Meiracker AH. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64:1282-1289. doi: 10.1161/HYPERTENSIONAHA.114.04187.
9. Salas SP, Marshall G, Gutiérrez BL, Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension. 2006;47:203-208. doi: 10.1161/01. HYP.0000200042.64517.19.
10. Gennari-Moser C, Khankin EV, Escher G, Burkhard F, Frey BM, Karumanchi SA, Frey FJ, Mohaupt MG. Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension. 2013;61:1111-1117. doi: 10.1161/HYPERTENSIONAHA.111.00575.
11. Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-Møller B, Jespersen B, Bistrup C, Jensen BL. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension. 2012;60:1346-1351. doi: 10.1161/HYPERTENSIONAHA.112.198879.
12. Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD, Arthur JM; Investigators SA. Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol. 2013;8:184-193. doi: 10.2215/CJN.06280612.
13. Verdonk K, Visser W, Russcher H, Danser AH, Steegers EA, van den Meiracker AH. Differential diagnosis of preeclampsia: remember the soluble fms-like tyrosine kinase 1/placental growth factor ratio. Hypertension. 2012;60:884-890. doi: 10.1161/HYPERTENSIONAHA. 112.201459.
14. Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD. Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol. 1991;165:724-727.
15. Florijn KW, Derkx FH, Visser W, Hofman HJ, Rosmalen FM, Wallenburg HC, Schalekamp MA. Elevated plasma levels of endothelin in preeclampsia. J Hypertens Suppl. 1991;9:S166-S167.
16. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension. 2001;37:485-489.
17. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55:394-398. doi: 10.1161/HYPERTENSIONAHA.109.141473.
18. Ortiz-Capisano MC. Endothelin inhibits renin release from juxtaglomerular cells via endothelin receptors A and B via a transient receptor potential canonical-mediated pathway. Physiol Rep. 2014;2:. doi: 10.14814/phy2.12240.
19. Ritthaler T, Scholz H, Ackermann M, Riegger G, Kurtz A, Krämer BK. Effects of endothelins on renin secretion from isolated mouse renal juxtaglomerular cells. Am J Physiol. 1995;268:F39-F45.
20. Krop M, Lu X, Verdonk K, Schalekamp MA, van Gool JM, McKeever BM, Gregg R, Danser AH. New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension. 2013;61:1075-1082. doi: 10.1161/HYPERTENSIONAHA.111.00967.
21. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, Urushihara M, Miyata K, Satou R, Hamm LL, Navar LG. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009;53:344-350. doi: 10.1161/HYPERTENSIONAHA.108.123802.
22. Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R, Danser AH. Urinary markers of intrarenal renin-angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15:81-88. doi: 10.1007/s11906-012-0326-z.
23. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, van den Meiracker AH, Danser AH. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens. 2011;29:2147-2155. doi: 10.1097/HJH.0b013e32834bbcbf.
24. Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens. 2013;31:1646-1652. doi: 10.1097/HJH.0b013e328362217c.
25. Nielsen AH, Hermann KL, Mazanti I, Poulsen K. Urinary excretion of inactive renin during blockade of the renal tubular protein reabsorption with lysine. J Hypertens. 1989;7:77-82.
26. Pinaud F, Bocquet A, Dumont O, Retailleau K, Baufreton C, Andriantsitohaina R, Loufrani L, Henrion D. Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats. Hypertension. 2007;50:96-102. doi: 10.1161/HYPERTENSIONAHA.106.085035.
27. Moltzer E, Verkuil AV, van Veghel R, Danser AH, van Esch JH. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension. 2010;55:516-522. doi: 10.1161/HYPERTENSIONAHA.109.145037.
28. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21:501-513. doi: 10.1517/13543784.2012.664131.
29. Treinen KA, Louden C, Dennis MJ, Wier PJ. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology. 1999;59:51-59. doi: 10.1002/(SICI)1096-9926(199901)59:1<51::AID-TERA10>3.0.CO;2-I
30. Koyama Y, Hayashi M, Nagae R, Tokuyama S, Konishi T. Endothelin-1 increases the expression of VEGF-R1/Flt-1 receptors in rat cultured astrocytes through ETB receptors. J Neurochem. 2014;130:759-769. doi: 10.1111/jnc.12770.
31. Spinella F, Caprara V, Cianfrocca R, Rosan L, Di Castro V, Garrafa E, Natali PG, Bagnato A. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis. 2014;35:840-848. doi: 10.1093/carcin/bgu018.